Neogenomics Inc NEO
We take great care to ensure that the data presented and summarized in this overview for NEOGENOMICS INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding NEO
View all-
Black Rock Inc. New York, NY19.7MShares$126 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA14.3MShares$91.5 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny6.72MShares$43.1 Million0.04% of portfolio
-
First Light Asset Management, LLC Edina, MN6.04MShares$38.8 Million7.36% of portfolio
-
Janus Henderson Group PLC London, X05.74MShares$36.9 Million0.03% of portfolio
-
State Street Corp Boston, MA5.09MShares$32.7 Million0.0% of portfolio
-
Greenhouse Funds Lllp Baltimore, MD4.71MShares$30.2 Million2.09% of portfolio
-
Macquarie Group LTD Australia, C34.68MShares$30 Million0.06% of portfolio
-
Schroder Investment Management Group London, X04.31MShares$27.7 Million0.04% of portfolio
-
Brown Advisory Inc3.87MShares$24.9 Million0.06% of portfolio
Latest Institutional Activity in NEO
Top Purchases
Top Sells
About NEO
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. The company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. It has a strategic alliance agreement and laboratory services agreement with Inivata Limited. The company was founded in 2001 and is headquartered in Fort Myers, Florida.
Insider Transactions at NEO
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Jun 01
2025
|
David Brian Perez Director |
BUY
Exercise of conversion of derivative security
|
Direct |
12,254
+26.56%
|
-
|
Jun 01
2025
|
Anthony P. Zook Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,424
-14.51%
|
-
|
Jun 01
2025
|
Anthony P. Zook Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,254
+34.19%
|
-
|
Jun 01
2025
|
Neil Gunn Director |
BUY
Exercise of conversion of derivative security
|
Direct |
12,254
+30.37%
|
-
|
Jun 01
2025
|
Elizabeth Floegel Director |
BUY
Exercise of conversion of derivative security
|
Direct |
12,254
+34.19%
|
-
|
Jun 01
2025
|
Alison L. Hannah Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,254
+8.55%
|
-
|
Jun 01
2025
|
Lynn A. Tetrault Director |
BUY
Exercise of conversion of derivative security
|
Direct |
12,254
+14.26%
|
-
|
Jun 01
2025
|
Michael Aaron Kelly Director |
BUY
Exercise of conversion of derivative security
|
Direct |
12,254
+21.78%
|
-
|
Jun 01
2025
|
Stephen M Kanovsky Director |
BUY
Exercise of conversion of derivative security
|
Direct |
12,254
+18.97%
|
-
|
Jun 01
2025
|
Felicia Williams Director |
BUY
Exercise of conversion of derivative security
|
Direct |
7,160
+50.0%
|
-
|
May 27
2025
|
Michael Aaron Kelly Director |
BUY
Open market or private purchase
|
Indirect |
5,000
+50.0%
|
$35,000
$7.6 P/Share
|
May 12
2025
|
Warren Stone Pres & Chief Operating Officer |
BUY
Open market or private purchase
|
Direct |
5,700
+5.0%
|
$45,600
$8.58 P/Share
|
May 11
2025
|
Warren Stone Pres & Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,341
-2.23%
|
-
|
May 11
2025
|
Warren Stone Pres & Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,613
+8.39%
|
-
|
May 11
2025
|
Jeffrey Scott Sherman Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,167
-1.85%
|
-
|
May 11
2025
|
Jeffrey Scott Sherman Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
13,005
+7.05%
|
-
|
May 11
2025
|
Alicia C Olivo EVP, GC & Business Development |
SELL
Payment of exercise price or tax liability
|
Direct |
1,584
-3.09%
|
-
|
May 11
2025
|
Alicia C Olivo EVP, GC & Business Development |
BUY
Exercise of conversion of derivative security
|
Direct |
6,503
+11.27%
|
-
|
May 09
2025
|
Lynn A. Tetrault Director |
BUY
Open market or private purchase
|
Indirect |
7,000
+50.0%
|
$56,000
$8.14 P/Share
|
May 07
2025
|
Stephen M Kanovsky Director |
BUY
Open market or private purchase
|
Direct |
4,000
+9.07%
|
$28,000
$7.78 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 12.3K shares |
---|---|
Exercise of conversion of derivative security | 322K shares |
Open market or private purchase | 75.1K shares |
Payment of exercise price or tax liability | 100K shares |
---|---|
Open market or private sale | 6.22K shares |